Pan-cancer molecular analysis of the RB tumor suppressor pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The retinoblastoma tumor suppressor gene (RB1) is a key regulator of cell cycle progression and is frequently altered in various cancers.
• Understanding the molecular landscape of the RB-pathway across diverse tumor types is essential for developing targeted therapies.

Purpose of the Study:

• To investigate the molecular features associated with the RB-pathway across 31 tumor types.
• To identify signatures of CDK4/6 activity and RB-dependency.
• To explore the relationship between RB1 alterations, CDK4/6 activity, and cancer progression.

Main Methods:

• Analysis of molecular features across 31 tumor types.
• Utilized an ER+ breast cancer model with targeted RB1 deletion.
• Identified CDK4/6-RB integrated signature.
• Correlated signature with gene expression and chromosomal alterations.

Main Results:

• RB1 alterations are mutually exclusive with CDK4/6 activity deregulation.
• A novel CDK4/6-RB integrated signature was identified and found to be prognostic in slower-growing tumors.
• Single copy loss of chromosome 13q (encompassing RB1) inversely correlated with the CDK4/6-RB integrated signature, suggesting a causal link.
• Discovered new tumor-specific pathways associated with RB-pathway activity based on gene correlations.

Conclusions:

• RB1 and CDK4/6 activity are key, mutually exclusive players in cancer, with implications for therapeutic strategies.
• The identified CDK4/6-RB integrated signature offers prognostic value and insights into RB-pathway function.
• Further research into RB-pathway-associated genes can uncover novel therapeutic targets.